ORCHPHARMA Stock Overview
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orchid Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,084.35 |
| 52 Week High | ₹1,359.95 |
| 52 Week Low | ₹381.35 |
| Beta | 2.42 |
| 1 Month Change | 3.10% |
| 3 Month Change | 52.09% |
| 1 Year Change | 176.69% |
| 3 Year Change | -27.64% |
| 5 Year Change | n/a |
| Change since IPO | 5,924.17% |
Recent News & Updates
Shareholder Returns
| ORCHPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.8% | 2.3% | 2.6% |
| 1Y | 176.7% | 56.7% | 45.0% |
Return vs Industry: ORCHPHARMA exceeded the Indian Pharmaceuticals industry which returned 57.2% over the past year.
Return vs Market: ORCHPHARMA exceeded the Indian Market which returned 46.6% over the past year.
Price Volatility
| ORCHPHARMA volatility | |
|---|---|
| ORCHPHARMA Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ORCHPHARMA's share price has been volatile over the past 3 months.
Volatility Over Time: ORCHPHARMA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 838 | Manish Dhanuka | www.orchidpharma.com |
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company’s multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services.
Orchid Pharma Limited Fundamentals Summary
| ORCHPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹55.00b |
| Earnings (TTM) | ₹1.25b |
| Revenue (TTM) | ₹8.12b |
44.2x
P/E Ratio6.8x
P/S RatioIs ORCHPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORCHPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹8.12b |
| Cost of Revenue | ₹4.92b |
| Gross Profit | ₹3.20b |
| Other Expenses | ₹1.96b |
| Earnings | ₹1.25b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.56 |
| Gross Margin | 39.44% |
| Net Profit Margin | 15.34% |
| Debt/Equity Ratio | 13.3% |
How did ORCHPHARMA perform over the long term?
See historical performance and comparison